PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 26, 2026Pathogens0 citationsOpen Access

Prescribed RNA Particle Vaccine Against Porcine Sapovirus Enhances Virus-Neutralizing Antibody Titers in Colostrum and Milk

View Full Paper
BABikash AryalSSSarah SnelsonTPThomas Petznick

Key Result

An RNA particle vaccine containing the PoSaV VP1 gene administered to pregnant sows significantly increased viral neutralizing antibody titers in colostrum and milk at 1-week post-farrowing.

Key Points

  • The aim is to evaluate the efficacy of an RNA particle vaccine against porcine sapovirus in boosting antibody levels in colostrum and milk of vaccinated sows.
  • Pregnant sows and gilts (n=15) were vaccinated intramuscularly with RNA vaccine twice.
  • Virus-neutralizing antibody levels in colostrum and milk were assessed at 1, 2, and 3 weeks post-farrowing.
  • Fecal shedding of PoSaV in piglets was analyzed using reverse transcription-quantitative PCR.
  • Vaccinated sows showed significantly higher VN antibody titers in colostrum and milk at 1 week post-farrowing compared to controls.
  • All piglets from vaccinated sows tested negative for PoSaV and had similar birth and weaning weights.
  • High VN antibody levels persisted in colostrum and milk for at least three weeks post-farrowing.

Structured PICO

Does an RNA particle vaccine against PoSaV increase viral neutralizing antibodies in colostrum and milk in pregnant sows and gilts?

P
Population
Pregnant sows and gilts in a commercial farm (n=15 in the vaccinated group: 13 sows and 2 gilts)
I
Intervention
RNA particle vaccine containing the PoSaV VP1 gene, administered intramuscularly twice
C
Comparator
Non-vaccinated controls
O
Outcome
Viral neutralizing (VN) antibodies in colostrum and milk collected at 1, 2, and 3 weeks post-farrowingsurrogate

An RNA particle vaccine against porcine sapovirus enhances virus-neutralizing antibody titers in the colostrum and milk of vaccinated sows.

Limitations

  • Future vaccination-challenge studies are warranted to confirm the efficacy of this vaccine.
  • Future vaccination-challenge studies are warranted to confirm the efficacy of this vaccine

Abstract

Confirmed porcine sapovirus (PoSaV) infection in young pigs have been increasing in swine farms; however, studies evaluating strategies to control PoSaV under field conditions remain scarce. In a commercial farm, one group of pregnant sows and gilts (n = 13 sows and 2 gilts) were vaccinated intramuscularly twice with an RNA particle vaccine containing the PoSaV VP1 gene, while the other group served as non-vaccinated controls. We evaluated the viral neutralizing (VN) antibodies in colostrum and milk collected at 1, 2, and 3 weeks post-farrowing. Fecal PoSaV shedding in 2-week- and 3-week-old piglets from both groups was assessed by reverse transcription-quantitative PCR. Body weight was measured at birth and 3 weeks of age when piglets were weaned. The vaccination group had higher VN antibody titers than the non-vaccinated group in colostrum and milk samples, with significance for colostrum and milk samples at 1-week post-farrowing. The colostrum and milk samples from both groups contained high VN antibody titers (>103.5 VNT50/mL) and remained high for at least three weeks, suggesting previous exposure to PoSaV. Corresponding to these high VN titers, all piglets were negative for PoSaV and had similar body weights at birth and 3 weeks of age. Future vaccination-challenge studies are warranted to confirm the efficacy of this vaccine.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Aryal et al. (2026) studied Porcine sapovirus (PoSaV) infection. RNA particle vaccine containing the PoSaV VP1 gene vs. Non-vaccinated controls was evaluated on Viral neutralizing (VN) antibodies in colostrum and milk. An RNA particle vaccine containing the PoSaV VP1 gene administered to pregnant sows significantly increased viral neutralizing antibody titers in colostrum and milk at 1-week post-farrowing.

synapsesocial.com/papers/6a153b00b5d9c58d83e8d3f1https://doi.org/10.3390/pathogens15060564
Ask AI
Helpful
Bookmark
Share
View Full Paper